The interleukin-6-174 C allel is associated with early acute rejection in pediatric kidney allografts
Küçük Resim Yok
Tarih
2004
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
lnterlökin-6 (IL-6) inflamasyon, konakçı savunması ve doku hasarında önemli rol oynayan çok işlevli bir sitokindir. Daha çok proinflamatuar sitokin olarak kabul edilmekle birlikte, son zamanlarda IL-6'nm immunsupressif rolü de saptanmıştır. Bu çalışmada, IL-6 -174 G/C promoter genotipinin, 55 böbrek nakli hastasından 14'ünde görülen akut rejeksiyona etkisi incelenmiştir. Akut rejeksiyon gözlenen 14 hastada, erken (ilk 3 ay içinde) akut rejeksiyon görülmesinin -174 C allel taşıyanlarda, taşımayanlara oranla anlamlı şekilde daha fazla olduğu bulunmuştur (%33,3 ile %10,3 p<0.05). Bu çalışmanın sonuçları, -174 C allel taşıyanlarda erken akut rejeksiyon riskinin daha fazla olduğu ve taşımayanlara oranla 4,3 kat daha fazla rölatif risk altında olduğunu düşündürmektedir.
lnterleukin-6 (IL-6) is a pleiotropic cytokine with a central role in inflammation, host defense and tissue injury. Although it is considered as predominantly proinflammatory cytokine; recently, IL-6 has been recognized as having additional immunosuppressive properties. In this study, we investigated the impact of IL-6 -174 G/C promoter genotype on acute rejection in 14 patients out of 55 kidney recipients. In 14 acute rejection presenting patients, early acute rejection (within first 3 months) was found significantly frequent in -174 C allel carriers, compared to non-carriers (33.3% vs 10.3% p<0.05). Our results imply a higher risk of early acute rejection in carriers of -174 C allel compared to non-carriers, and the relative risk of early acute rejection is 4.3 fold higher in IL-6 -174 C allel carrriers.
lnterleukin-6 (IL-6) is a pleiotropic cytokine with a central role in inflammation, host defense and tissue injury. Although it is considered as predominantly proinflammatory cytokine; recently, IL-6 has been recognized as having additional immunosuppressive properties. In this study, we investigated the impact of IL-6 -174 G/C promoter genotype on acute rejection in 14 patients out of 55 kidney recipients. In 14 acute rejection presenting patients, early acute rejection (within first 3 months) was found significantly frequent in -174 C allel carriers, compared to non-carriers (33.3% vs 10.3% p<0.05). Our results imply a higher risk of early acute rejection in carriers of -174 C allel compared to non-carriers, and the relative risk of early acute rejection is 4.3 fold higher in IL-6 -174 C allel carrriers.
Açıklama
Anahtar Kelimeler
Cerrahi
Kaynak
Ege Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
43
Sayı
2
